Interpretation of the 2023 updates to the National Institute for Health and Care Excellence Guidelines on Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification
10.3760/cma.j.cn115682-20240113-00252
- VernacularTitle:NICE?《心血管疾病风险评估与降低，包括脂质调节》指南2023年新增部分解读
- Author:
Ying REN
1
;
Rui ZHANG
;
Shilan LUO
Author Information
1. 重庆医科大学附属第二医院老年医学科，重庆 400010
- Keywords:
Cardiovascular disease;
Risk assessment;
Statins;
Guideline;
Interpretation
- From:
Chinese Journal of Modern Nursing
2024;30(25):3361-3367
- CountryChina
- Language:Chinese
-
Abstract:
This article provides an interpretation of the newly added sections in the 2023 guidelines titled Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification published by the National Institute for Health and Care Excellence (NICE). The new sections cover various aspects such as risk assessment tools for the primary prevention of cardiovascular disease (CVD), cardiovascular protective diets, and the use of aspirin and statins for both primary and secondary prevention of CVD. This interpretation aims to provide scientific guidance for CVD risk assessment and reduction in China.
